Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 7/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.49 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496238 | 1.00 | GAA (0.53) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3496284 | 0.88 | GAA (0.57) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3496286 | 0.88 | GAA (0.57) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3493807 | 0.86 | KIF11 (0.58) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3493810 | 0.86 | KIF11 (0.58) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3492860 | 0.85 | KIF11 (0.64) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3492856 | 0.85 | KIF11 (0.64) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3496084 | 0.85 | KIF11 (0.47) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3496081 | 0.85 | KIF11 (0.47) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3494990 | 0.84 | KIF11 (0.71) | GAAKIF11MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | claimed |
| WO-2006060737-A2 | MITOTIC KINESIN INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093767-A1 | Mitotic Kinase Inhibitors | BUB1B, BUB1, PLK1 | GAA 1160/4885KIF11 18/4885MAP1LC3B 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.